Teva Pharmaceutical Industries Limited (NASDAQ:TEVA) develops, manufactures, markets, and distributes pharmaceutical products worldwide. This dividend achiever has paid dividends since 1984, and has increased them for 13 years in a row. The company's last dividend increase was in February 2013 when the board of directors approved a 25% increase in the quarterly distribution to one NIS/share. The company's peer group includes Actavis (ACT), Taro Pharmaceutical (NYSE:TARO), and Revlon (NYSE:REV).
Over the past decade, this dividend growth stock has delivered an annualized total return of 8.10% to its shareholders.
Click to enlarge images.
The company has managed to deliver a 7.30% average increase in annual EPS since 2003. Analysts expect Teva Pharmaceutical to earn $5.07 per share in 2013 and $5.54 per share in 2014. In comparison, the company earned $2.25/share in 2012. Over the next five years, analysts expect EPS to rise by 6.81%/annum.
Earnings per share have been following a general uptrend, which has been quite volatile, however. The company's U.S. operations have benefited from the recent launches of new generic products such as Lexapro and Actos. The patent cliff experienced by big pharma is beneficial for generics manufacturers such as Teva. Generics account for over half of the company's sales. The company has intense competition in the generic pharmaceuticals market, where being first to file might offer a slight competitive advantage to the filer. However, Teva is not immune to the patent cliff itself. Its multiple-sclerosis drug Copaxone, accounting for 17% of sales in 2012, will face competition from Mylan Laboratories as early as 2015.
Future growth could also be realized from strategic acquisitions. The firm is expecting to benefit from the 2011 acquisition of Cephalon in terms of synergies. Teva expects to realize annual cost synergies of at least $500 million in year three following the transaction's close. Teva's significantly broader portfolio will permit marketing and sales synergies and enhance profitability.
The return on equity for Teva has been on the decline from a high of 27% in 2003. Currently, it is below 10%, but if earnings projections materialize it could go up to 15%. I generally want to see at least a stable return on equity over time. I use this indicator to assess whether management is able to put extra capital to work at sufficient returns.
The annual dividend payment in U.S. dollars has increased by 27.60% per year over the past decade, which is higher than the growth in EPS.
A 27% growth in distributions translates into the dividend payment doubling almost every two and a half years on average. If we look at historical data, going as far back as 1990, one would notice that the company has managed to double distributions every three years on average. The dividend payout ratio has increased from 12% in 2003 to 46% in 2012. A lower payout is always a plus since it leaves room for consistent dividend growth, minimizing the impact of short-term fluctuations in earnings.
Currently, Teva is attractively valued at 17.20 times earnings, yields 2.80%, and has a sustainable distribution. Unfortunately, I am not certain if it has the durable competitive advantages that would help it differentiate itself from competitors. It looks as if in the generic drugs industry, companies do not have any competitive advantages related to branding that would allow them to charge premium prices. In the long run, commodity producers cannot realize excessive profits that would translate into fat future dividends. As a result, I do not plan on initiating a position in the stock.
Disclosure: I have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any company whose stock is mentioned in this article.